CStone Pharma of Suzhou has dosed the first patient in a China clinical trial of avapritinib as a treatment for gastrointestinal stromal tumors (GIST). One year ago, CStone acquired China rights to the candidate from Blueprint Medicines of Boston in a three-drug deal worth up to $386 million. CStone is conducting a Phase I/III bridging trial that will be part of Blueprint’s global Phase III trial of avapritinib as a third/fourth line treatment for GIST, compared to Bayer’s Stivarga® (regorafenib). Source: China Biotoday
